ArticleMaterials today. Bio2025
Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma.Clinical and translational medicine · 2026Review
- Self-healing hydrogels: mechanisms and applications in biomedical and environmental fields.Biodegradation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer vaccine research has made significant progress in antigen discovery, delivery systems, and combination therapies. However, optimizing antigen selection and delivery remains a current challenge. To address this, we utilized oxidatively treated tumor cells as a source of antigens, effectively enhancing their immunogenicity. Inspired by the antigen delivery capabilities of dendritic cells (DCs) via extracellular vesicles, we developed a novel biomimetic nanovesicle vaccine, diA-MADCVac. This vaccine inherits the targeting ability of DCs, enabling precise antigen delivery to lymph nodes. Moreover, as a carrier, it efficiently delivers both adjuvants and intact tumor antigens, thereby playing a synergistic role in activating the immune system. Result: By targeting lymph nodes, diA-MADCVac effectively induces DCs maturation, activating tumor-specific T cell responses and generating trained immune memory. Furthermore, in a melanoma mouse model, diA-MADCVac significantly altered the tumor microenvironment, triggering a strong anti-tumor immune response and inhibiting tumor growth. This effect was characterized by increased secretion of cytokines such as IFN-γ and TNF-α in the tumor, along with a higher number of infiltrating T cells, which enhanced the immune system's tumor-killing capacity. Conclusion: This study introduces a novel vaccination strategy utilizing the DC-derived nanovesicle vaccine, diA-MADCVac. Systematic studies and experimental validation demonstrate that diA-MADCVac exhibits excellent biocompatibility, ensuring its safety for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.